ImmunoPrecise Antibodies Ltd. (HYFT) Cash Flow Statement
Where HYFT’s cash came from and went, FY2026
April 30, 2026 · Canadian dollars- Cash from operations
- −C$12.3M
- Capital expenditures
- C$391,896 2.6% of revenue
- Free cash flow
- −C$12.7M −82.7% margin
- Returned to shareholders
- —
- Change in cash
- C$837,546 cash at year-end C$11.3M
Cash from operations
−C$12.3M
Capital expenditures
−C$391,896
Investments (net)
+C$14.3M
Acquisitions & other
−C$525,852
Net borrowing (repayment)
−C$782,000
Shares issued
+C$897,000
Currency & other
−C$342,859
Change in cash
C$837,546
Drawn to scale: where the cash came from and how it was used. Hover for values.
HYFT operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
HYFT cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −C$721,651FY2017 | −C$12.3MFY2026 | — | |
| Capital expenditures | C$530,750FY2017 | C$391,896FY2026 | −3.3%/yr | |
| Free cash flow | −C$1.3MFY2017 | −C$12.7MFY2026 | — | |
| Free cash flow margin | −47.6%FY2017 | −82.7%FY2026 | −35.1 pts | |
| Stock-based compensation | C$198,032FY2017 | C$1.3MFY2026 | +23.0%/yr | |
| Capex / revenue | 20.2%FY2017 | 2.6%FY2026 | −17.6 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
HYFT cash flow by activity
OperatingInvestingFinancingChange in cash
HYFT net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
HYFT cash flow statement in Canadian dollars
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −C$14.9M | −C$30.2M | −C$27.2M | −C$26.6M | −C$16.7M | −C$7.3M | −C$4.9M | −C$7.6M | −C$5.2M | −C$5.4M |
| Depreciation & amortization | C$1.6M | C$5.1M | C$5.7M | C$6.7M | C$3.8M | C$3.7M | C$3.4M | C$2.3M | C$458,079 | C$50,609 |
| Stock-based compensation | C$1.3M | C$445,000 | C$1.5M | C$1.9M | C$3.1M | C$2.7M | C$739,011 | C$1.1M | C$1.2M | C$198,032 |
| Change in working capital | −C$2.0M | C$276,990 | C$2.4M | −C$3.3M | C$582,000 | −C$1.0M | −C$1.1M | C$580,640 | −C$193,383 | C$380,689 |
| Other non-cash items | C$1.8M | C$18.0M | C$13.3M | C$1.4M | −C$646,000 | C$1.3M | C$526,966 | C$452,835 | C$268,574 | C$4.0M |
| Cash from operating activities | −C$12.3M | −C$6.4M | −C$4.2M | −C$19.8M | −C$9.9M | −C$600,000 | −C$1.4M | −C$3.2M | −C$3.4M | −C$721,651 |
| Investing activities | ||||||||||
| Capital expenditures | −C$391,896 | −C$799,000 | −C$1.4M | −C$1.5M | −C$1.3M | −C$1.4M | −C$575,642 | −C$645,058 | −C$345,487 | −C$530,750 |
| Investments (net) | C$14.3M | −C$799,000 | −C$1.6M | −C$2.0M | −C$5.2M | — | — | — | — | — |
| Acquisitions & other investing | −C$525,852 | C$799,000 | C$1.4M | C$1.5M | C$1.3M | −C$1.0M | −C$1.0M | −C$1.6M | −C$6.8M | C$356,137 |
| Cash from investing activities | C$13.3M | −C$799,000 | −C$1.6M | −C$2.0M | −C$5.2M | −C$2.5M | −C$1.6M | −C$2.2M | −C$7.2M | −C$174,613 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | — | −C$90,000 |
| Net borrowing (repayment) | −C$782,000 | C$2.7M | −C$1.3M | −C$1.3M | −C$962,000 | — | — | — | — | — |
| Shares issued | C$897,000 | C$12.2M | C$2.4M | C$716,000 | C$3.9M | C$0 | C$0 | C$0 | C$0 | C$0 |
| Other financing | −C$1,765 | C$0 | C$0 | C$0 | −C$5,000 | C$43.4M | C$174,701 | C$9.4M | C$9.8M | C$3.3M |
| Cash from financing activities | C$113,235 | C$14.9M | C$1.0M | −C$621,000 | C$2.9M | C$43.4M | C$174,701 | C$9.4M | C$9.8M | C$3.2M |
| Summary | ||||||||||
| Net change in cash | C$837,546 | C$7.2M | −C$4.8M | −C$21.7M | −C$11.8M | C$39.1M | −C$2.8M | C$3.7M | −C$772,312 | C$2.2M |
| Cash at end of period | C$11.3M | C$10.8M | C$3.5M | C$8.4M | C$30.0M | C$41.8M | C$2.7M | C$5.5M | C$1.8M | C$2.6M |
| Free cash flow | −C$12.7M | −C$7.2M | −C$5.6M | −C$21.3M | −C$11.2M | −C$2.0M | −C$2.0M | −C$3.9M | −C$3.8M | −C$1.3M |
| Free cash flow margin | −82.7% | −29.4% | −23.0% | −103.2% | −57.7% | −11.3% | −13.4% | −35.3% | −69.1% | −47.6% |
| Capex / revenue | 2.6% | 3.3% | 5.7% | 7.2% | 6.5% | 8.0% | 3.9% | 5.9% | 6.3% | 20.2% |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −C$6.2M | −C$3.8M | −C$3.9M | −C$3.2M | −C$3.0M | −C$2.2M | −C$21.5M | −C$2.6M | −C$4.0M | −C$18.0M | −C$2.0M | −C$2.4M |
| Depreciation & amortization | C$270,158 | C$235,936 | C$213,465 | C$207,000 | C$942,000 | C$913,000 | C$1.4M | C$1.0M | C$1.4M | C$1.6M | C$1.3M | C$1.4M |
| Stock-based compensation | C$740,000 | C$810,000 | C$258,000 | C$152,000 | C$55,000 | C$53,000 | C$70,000 | C$157,000 | C$165,000 | C$237,000 | C$1.0M | C$297,000 |
| Change in working capital | C$1.2M | C$589,633 | C$20,016 | −C$414,000 | −C$2.3M | −C$410,000 | C$723,000 | −C$649,000 | C$1.1M | −C$174,000 | −C$304,000 | C$1.0M |
| Other non-cash items | −C$132,645 | −C$310,774 | C$449,238 | C$380,000 | C$41,000 | C$465,000 | C$18.1M | −C$234,202 | −C$487,000 | C$13.8M | −C$690,553 | −C$259,000 |
| Cash from operating activities | −C$4.1M | −C$2.5M | −C$2.9M | −C$2.9M | −C$4.2M | −C$1.1M | −C$1.2M | −C$2.2M | −C$1.8M | −C$2.6M | −C$666,000 | −C$18,000 |
| Investing activities | ||||||||||||
| Capital expenditures | −C$79,218 | −C$15,513 | −C$30,576 | −C$74,000 | −C$282,000 | −C$359,000 | −C$112,000 | −C$65,000 | −C$263,000 | −C$1.1M | −C$165,000 | −C$299,000 |
| Investments (net) | — | — | — | — | −C$594,000 | −C$359,000 | −C$112,000 | −C$65,000 | −C$263,000 | −C$1.1M | — | — |
| Acquisitions & other investing | −C$1 | C$165,818 | C$14.0M | C$0 | C$282,000 | C$359,000 | C$112,000 | C$65,000 | C$263,000 | C$1.1M | C$222,000 | −C$13,000 |
| Cash from investing activities | −C$79,219 | C$150,305 | C$14.0M | −C$74,000 | −C$594,000 | −C$359,000 | −C$112,000 | −C$65,000 | −C$263,000 | −C$1.1M | C$57,000 | −C$312,000 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | −C$77,000 | −C$48,000 | — | — | — | — | — | — | — |
| Net borrowing (repayment) | −C$179,000 | −C$256,000 | −C$102,000 | −C$101,000 | −C$323,000 | −C$435,000 | −C$158,000 | C$1.1M | C$2.2M | — | — | — |
| Shares issued | C$525,000 | C$0 | C$0 | C$0 | C$0 | C$17,000 | C$10.7M | C$1.0M | C$491,000 | C$1.4M | C$0 | C$0 |
| Other financing | C$5,410 | −C$21,772 | −C$13.0M | C$14.3M | C$0 | C$0 | C$0 | C$0 | C$0 | −C$302,000 | C$613,000 | −C$310,000 |
| Cash from financing activities | C$351,410 | −C$277,772 | −C$13.1M | C$14.1M | −C$371,000 | −C$418,000 | C$10.5M | C$2.1M | C$2.7M | C$1.1M | C$613,000 | −C$310,000 |
| Summary | ||||||||||||
| Net change in cash | −C$4.1M | −C$2.8M | −C$1.9M | C$11.6M | −C$5.8M | −C$2.2M | C$9.4M | −C$379,000 | C$455,000 | −C$2.7M | C$185,000 | −C$709,000 |
| Cash at end of period | C$7.7M | C$11.3M | C$14.2M | C$16.6M | C$5.0M | C$10.8M | C$13.0M | C$3.6M | C$4.0M | C$3.5M | C$6.3M | C$6.1M |
| Free cash flow | −C$4.2M | −C$2.5M | −C$3.0M | −C$2.9M | −C$4.5M | −C$1.5M | −C$1.3M | −C$2.3M | −C$2.1M | −C$3.8M | −C$501,000 | −C$317,000 |
| Free cash flow margin | −107.5% | −61.8% | −72.3% | −71.4% | −142.2% | −21.5% | −21.4% | −86.2% | −84.4% | −58.4% | −8.1% | −5.2% |
| Capex / revenue | 2.0% | 0.4% | 0.7% | 1.8% | 8.9% | 5.1% | 1.8% | 2.4% | 10.6% | 17.4% | 2.7% | 4.9% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Canadian dollars as reported; data from EODHD.
HYFT cash generation
In fiscal 2026 (ended April 30, 2026), ImmunoPrecise Antibodies generated -C$12.3 million of cash from operations and spent C$0.4 million on capital expenditures, leaving free cash flow of -C$12.7 million, −82.7% of revenue. Cash and equivalents rose by C$0.8 million over the year.
Related: HYFT income statement, HYFT balance sheet. See the HYFT stock overview for the latest quote and news.
HYFT cash flow FAQ
What is ImmunoPrecise Antibodies's free cash flow?
ImmunoPrecise Antibodies's free cash flow was -C$12.7 million in fiscal 2026: -C$12.3 million of operating cash flow minus C$0.4 million of capital expenditures It was -C$7.2 million a year earlier..
How much cash does ImmunoPrecise Antibodies generate from operations?
ImmunoPrecise Antibodies generated -C$12.3 million of cash from operating activities in fiscal 2026.
How much does ImmunoPrecise Antibodies spend on capital expenditures?
ImmunoPrecise Antibodies spent C$0.4 million on capital expenditures in fiscal 2026, 2.6% of revenue, compared with C$0.8 million the year before.